Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Income (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Income for 3 consecutive years, with -$21.9 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 20.06% to -$21.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$89.8 million through Dec 2025, down 33.48% year-over-year, with the annual reading at -$89.8 million for FY2025, 33.48% down from the prior year.
  • Operating Income for Q4 2025 was -$21.9 million at Artiva Biotherapeutics, up from -$22.9 million in the prior quarter.
  • The five-year high for Operating Income was $12.7 million in Q4 2023, with the low at -$22.9 million in Q3 2025.
  • Average Operating Income over 3 years is -$13.2 million, with a median of -$18.3 million recorded in 2024.
  • The sharpest move saw Operating Income plummeted 269.6% in 2024, then dropped 20.06% in 2025.
  • Over 3 years, Operating Income stood at $12.7 million in 2023, then tumbled by 244.2% to -$18.3 million in 2024, then dropped by 20.06% to -$21.9 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$21.9 million, -$22.9 million, and -$22.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.